A team published their results in Science Immunology to examine whether intestinal microbes influence vulnerability to secondary bacterial infections after a respiratory virus. They studied segmented filamentous bacteria (SFB) in mice infected with influenza A and then exposed the animals to common respiratory bacterial pathogens.
The investigators used several bacteria that commonly cause post-influenza pneumonia. They found that SFB gave marked protection against these highly lethal secondary infections. The protective effect worked through lung immune cells: SFB altered the behaviour of alveolar macrophages so the cells resisted the dysfunction that normally follows influenza.
Lead author Vu Ngo noted that adding one gut species changed how lung macrophages respond. Senior author Andrew T. Gewirtz said the team hopes to use this mechanism to develop new treatments. The study was funded by NIAID of the NIH.
Difficult words
- intestinal — relating to the intestines or the gut
- microbe — very small living organism, often single-celledmicrobes
- vulnerability — a condition of being easily harmed or infected
- secondary — happening after an earlier event
- pathogen — a microbe that causes disease in a hostpathogens
- alveolar macrophage — an immune cell in the lungs that eats microbesalveolar macrophages
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could a single gut species change the behaviour of immune cells in the lungs? Give one possible explanation.
- Would you support developing treatments based on gut microbes? Why or why not?
- How might these findings change care for people who have had influenza?
Related articles
Gut has a backup system for IgA antibodies
Researchers found two different routes that make IgA antibodies in the gut. Early IgA often comes from non‑germinal center cells but later from germinal centers; both types showed similar specificity and mutations, which may help vaccine design.
New oral Listeria vaccine shows promise against colorectal cancer
Researchers report a modified oral vaccine made from Listeria that primes immune cells in the gut and limits tumor growth in mice. The vaccine worked best when combined with immune checkpoint inhibitors and caused few side effects.